IP Library › Granted Patent US 9,682,095
Granted Patent B2
US 9,682,095 · App. 13/734,414 · Granted Jun 20, 2017

MiRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway

Inventors: Eugene Berezikov (Haren, NL); Jos Bernard Poell (Utrecht, NL); Willemijn Maria Gommans (Voorschoten, NL); Rick Jan van Haastert (Amersfoort, NL); Andreas Alphons F. L. van Puijenbroek (Boxtel, NL); Roeland Quirinus Jozef Schaapveld (Bussum, NL); Gregoire Pierre Andre Prevost (Antony, FR)
Assignee: INTERNA TECHNOLOGIES B.V.
A61K31/7088C12N15/111C12N15/113C12N15/1135C12Q1/6809C12N2310/113C12N2310/141C12N2320/10C12N2320/31C12N2330/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,682,095
App. No.
13/734,414
Granted
Jun 20, 2017
Kind
B2
Abstract

The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with melanoma or a disease or a condition associated with activated BRAF pathway.

Claims (45)

1. A method for inhibiting growth and/or reducing viability of melanoma cells or of cells containing an activating BRAF mutation wherein said cells are melanoma cells or ovarian cancer cells, said method comprising: administering to said cells an effective amount of at least one miRNA molecule or a composition comprising an effective amount of said at least one miRNA molecule, wherein said at least one miRNA molecule is selected from the group consisting of:

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:164 and 165 and having at least 70% identity with SEQ ID NO:103 or 104 (miRNA-96),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:172 and having at least 70% identity with SEQ ID NO:111 (miRNA-203),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:160 and 161 and having at least 70% identity with SEQ ID NO:99 or 100 (miRNA-10b),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:162 and 163 and having at least 70% identity with SEQ ID NO:101 or 102 (miRNA-18b),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:167, 168 and 169 and having at least 70% identity with SEQ ID NO:106 or 107 or 108 (miRNA-129),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:166 and having at least 70% identity with SEQ ID NO:105 (miRNA-128),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:170 and having at least 70% identity with SEQ ID NO:109 (miRNA-184),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:171 and having at least 70% identity with SEQ ID NO:110 (miRNA-190b),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:173 and having at least 70% identity with SEQ ID NO:112 (miRNA-3157),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:177 and having at least 70% identity with SEQ ID NO:116 (miRNA-133a),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:183 and 184 and having at least 70% identity with SEQ ID NO:122 or 123 (miRNA-200c),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:190 and having at least 70% identity with SEQ ID NO:129 (miRNA-610),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:186 and 187 and having at least 70% identity with SEQ ID NO:125 or 126 (miRNA-182),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:174, 175 and 176 and having at least 70% identity with SEQ ID NO:113, 114 or 115 (miRNA-16),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:185 and having at least 70% identity with SEQ ID NO:124 (miRNA-95),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:188 and 189 and having at least 70% identity with SEQ ID NO:127 or 128 (miRNA-193a),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:181 and 182 and having at least 70% identity with SEQ ID NO:120 or 121 (miRNA-497),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:178, 179 and 180 and having at least 70% identity with SEQ ID NO:117, 118 or 119 (miRNA-509),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:157, 158 and 159 and having at least 70% identity with SEQ ID NO:96, 97 or 98 (miRNA-7) and/or

a precursor of said miRNA molecule.

2. A method according to claim 1 , wherein said at least one miRNA molecule is selected from the group consisting of: miRNA-16, miRNA-10b, miRNA-18b, miRNA-96, miRNA-203, miRNA-7, miRNA-190b, and/or miRNA-128, and/or an isomiR and/or a precursor of said miRNA molecule.

3. A method according to claim 1 , wherein said at least one miRNA molecule is selected from the group consisting of:

miRNA-96 and/or miRNA-16 and/or an isomiR and/or a precursor thereof;

miRNA-16 and/or miRNA-10b and/or an isomiR and/or a precursor thereof;

miRNA-96 and/or miRNA-10b and/or an isomiR and/or a precursor thereof;

miRNA-96 and/or miRNA-203 and/or an isomiR and/or a precursor thereof;

miRNA-128 and/or miRNA-10b* and/or an isomiR and/or a precursor thereof; miRNA-16 and/or miRNA-203 and/or an isomiR and/or a precursor thereof;

miRNA-190b and/or miRNA-203 and/or an isomiR and/or a precursor thereof;

miRNA-18b and/or miRNA-203 and/or isomiR and/or precursor thereof; and

miRNA-7 and/or miRNA-203 and/or isomiR and/or precursor thereof.

4. A method according to claim 1 , wherein said at least one miRNA molecule is selected from the group consisting of: miRNA-96, miRNA-129, miRNA-509, miRNA-128, and/or miRNA-16, and/or an isomiR and/or a precursor thereof.

5. A method according to claim 1 , wherein said at least one miRNA molecule is selected from the group consisting of miRNA-96 and/or miRNA-129 and/or an isomiR and/or precursor thereof.

6. A method according to claim 1 , wherein said at least one miRNA molecule is: miRNA-16, miRNA-10b, miRNA-96, miRNA-203, miRNA-129, miRNA-509, miRNA-128, and/or miRNA-18b and/or isomiR and/or precursor thereof.

7. A method according to claim 1 , wherein said at least one miRNA molecule is miRNA-16 and/or miRNA-96 and/or an isomiR and/or precursor thereof.

8. A method according to claim 1 , wherein said composition further comprises an miRNA molecule, isomiR, or precursor thereof, selected from the group consisting of:

a) at least one of miRNA-137, Let-7, and Let-7a, and/or an isomiR or a precursor thereof.

9. A method according to claim 1 , wherein said miRNA molecule is an miRNA-129 molecule or an isomiR thereof or a precursor thereof.

10. A method according to claim 1 , wherein said miRNA molecule is an miRNA-497 molecule or an isomiR thereof or a precursor thereof.

11. The method of claim 1 , wherein a precursor of said miRNA is administered.

12. The method of claim 1 , wherein said cells are melanoma cells.

13. The method of claim 12 wherein the miRNA molecule is an miRNA-3157 molecule or an isomiR thereof or a precursor thereof.

14. A method for inhibiting growth and/or reducing viability of melanoma cells or cells containing an activating BRAF mutation wherein said cells are melanoma cells or ovarian cancer cells, said method comprising: administering to said cells an effective amount of an miRNA molecule or an effective amount of a composition comprising an miRNA molecule, wherein said miRNA molecule is from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:173 and having at least 70% identity with SEQ ID NO:112 (miRNA-3157) or a precursor thereof.

15. The method of claim 1 , wherein an isomiR of said miRNA is administered.

16. The method of claim 1 , wherein the miRNA molecule is a modified miRNA molecule.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2013
From: BEREZIKOV, EUGENE; POELL, JOS BERNARD; GOMMANS, WILLEMIJN MARIA; VAN HAASTERT, RICJ JAN; VAN PUIJENBROEK, ANDREAS ALPHONS FRANCISCUS LUDOVICUS; SCHAAPVELD, ROELAND QUIRINUS; PREVOST, GREGOIRE PIERRE ANDRE
To: INTERNA TECHNOLOGIES B.V.; KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN
Reel/Frame 029802/0920 →
Priority Claims (1)
EP 10168592 · Jul 6, 2010 · regional
Continuity (3)
Continuation PCTNL2011050476 · Jul 1, 2011
Provisional Application 61361787 · Jul 6, 2010
Related Publication 20130109741A1 · May 2, 2013